Search Results
Aug 27, 2025, 15:28 ET The Galien Foundation Announces 2025 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"
Pulsed Field Ablation System Cresilon TRAUMAGEL®
More news about: The Galien Foundation
Aug 04, 2025, 08:30 ET Cresilon Announces Poster Presentation on TRAUMAGEL Case Study at the 2025 Military Health System Research Symposium
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced
More news about: Cresilon
Jun 19, 2025, 10:01 ET Hemostats Market Set to Attain Valuation of US$ 4,839 Million By 2033 Says Astute Analytica
plasma-derived products. TachoSil®, now owned by Corza Medical, dominates the ready-to-use fibrin patch niche with 83% segment share, while upstarts like Cresilon, Arch Therapeutics, and MedTrade are growing rapidly (>40% YoY) with differentiated offerings such as faster set times and robotic compatibility.
More news about: Astute Analytica
Jun 16, 2025, 08:20 ET Cresilon Announces International Distribution Agreement for VETIGEL with McCarthy Vet
NEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced
More news about: Cresilon
Jan 13, 2025, 08:30 ET Cresilon Announces U.S. Nationwide Launch of TRAUMAGEL
NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the
More news about: Cresilon
Sep 16, 2024, 08:30 ET Cresilon Selected to Exhibit TRAUMAGEL at Vizient Innovative Technology Exchange
NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has been selected
More news about: Cresilon